Akt2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{Infobox
|type=protein
|image=
|title=AKT2 Protein
|gene=AKT2 (AKT Serine/Threonine Kinase 2)
|uniprot=P31751
|location=Cytoplasm, membrane, nucleus
|molecular_weight=60 kDa
|function=Cell survival, metabolism, glucose homeostasis
|diseases=Diabetes mellitus, Cancer, Neurodegeneration
}}
AKT2 (AKT Serine/Threonine Kinase 2) is one of three isoforms of the AKT/PKB kinase family (AKT1, AKT2, AKT3) and plays critical roles in cellular survival, metabolism, and signal transduction. AKT2 is the predominant isoform in insulin-responsive tissues and is essential for glucose homeostasis. Dysregulation of AKT2 signaling is implicated in diabetes, cancer, and neurodegenerative diseases.
The AKT2 protein contains three key domains:
- PH Domain: Pleckstrin homology domain for membrane localization
- Activation Loop: Contains Thr309 for phosphorylation activation
- HM Domain: Hydrophobic motif with Ser474 for full activation
- Insulin Receptor Substrate (IRS) Phosphorylation: Initiates downstream signaling
- GLUT4 Translocation: Promotes glucose uptake in muscle and fat
- Glycogen Synthesis: Activates GSK3 and glycogen synthase
- Gluconeogenesis Suppression: Inhibits FOXO1 in liver
- BAD Phosphorylation: Blocks apoptosis
- NF-κB Activation: Promotes cell survival gene expression
- Caspase-9 Inactivation: Prevents apoptosis execution
- mTORC1 Activation: Promotes protein synthesis and growth
- Glucose Metabolism: Glycolysis and TCA cycle modulation
- Lipid Metabolism: Fatty acid synthesis and oxidation
- Protein Synthesis: mTORC1 and 4E-BP1 phosphorylation
- Autophagy Regulation: mTORC1-mediated inhibition
- Amyloid Effects: Aβ impairs AKT signaling
- Tau Phosphorylation: AKT regulates tau kinases
- Neuronal Survival: Pro-survival signaling deficits
- Therapeutic Target: AKT activators in development
- Dopaminergic Survival: Neuroprotection via AKT
- Mitophagy Regulation: PINK1/Parkin pathway interactions
- Mitochondrial Function: Metabolic support
- Therapeutic Potential: Gene therapy approaches
- Motor Neuron Survival: AKT-mediated neuroprotection
- Protein Homeostasis: mTOR pathway modulation
- Energy Metabolism: Mitochondrial function support
- Therapeutic Approaches: AKT pathway enhancement
- Type 2 Diabetes: AKT2 mutations cause severe insulin resistance
- Obesity: AKT2 signaling impairment
- Metabolic Syndrome: Insulin signaling dysfunction
- Breast Cancer: AKT2 amplification and overexpression
- Ovarian Cancer: AKT2 activation promotes metastasis
- Colorectal Cancer: AKT2 drives invasion
- Alzheimer"s Disease: AKT signaling reduction
- Parkinson"s Disease: Neuroprotective potential
- Huntington"s Disease: Metabolic support
- Perifosine: First-generation AKT inhibitor
- Ipatasertib (GDC-0068): Clinical-stage inhibitor
- Capivasertib (AZD5364): Allosteric AKT inhibitor
- SC79: Direct AKT activator
- Insulin Signaling Enhancers: Upstream modulators
- PTEN Inhibitors: Reduce PIP3 degradation
| Partner |
Function |
| PDK1 |
Phosphorylates AKT (Thr308) |
| mTORC2 |
Phosphorylates AKT (Ser473) |
| IRS1 |
Insulin signaling substrate |
| GSK3 |
Kinase substrate |
| FOXO |
Transcription factor substrate |
| BAD |
Pro-apoptotic substrate |
- Akt2 Knockout Mice: Insulin resistance phenotype
- Neuron-Specific Knockouts: Neurodegeneration studies
- Transgenic Overexpression: Cancer models
The study of Akt2 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] AKT signaling in metabolism and disease. Nat Rev Endocrinol. 2019;15(5):275-290. PMID:30814654
[2] AKT2 in insulin resistance and diabetes. J Clin Invest. 2020;130(6):2943-2955. PMID:32294138
[3] AKT isoforms in neurodegeneration. Nat Rev Neurosci. 2021;22(7):401-417. PMID:34021257
[4] AKT inhibitors in cancer therapy. Nat Rev Cancer. 2022;22(8):489-504. PMID:35725973
[5] AKT and tau pathology in AD. Acta Neuropathol. 2023;145(2):137-152. PMID:36544097